The Cardinal Conundrum: When Growth Meets Valuation Woes

Jim Cramer’s recent endorsement of Cardinal Health has sent shockwaves through the healthcare sector. Beneath the surface, however, lies a more complex story. The company’s ability to adapt and grow in a rapidly changing industry is undeniable, yet its valuation woes raise concerns about the sustainability of this momentum.

Cardinal’s shift towards specialty pharmaceuticals and higher-margin healthcare services has been remarkable. Its gradual transformation from a commoditized service provider to a specialized player has allowed it to consistently outperform peers such as McKesson and Cencora. The company’s fiscal fourth-quarter revenue may have missed estimates, but this is largely due to lower branded-drug prices and the shift towards generics.

Cardinal focuses on volume rather than revenue growth, a deliberate strategy that acknowledges the limitations of the current market. By emphasizing high volumes and attractive margins, the company attempts to insulate itself from fluctuations in drug pricing and distributor fees. This approach has yielded impressive results, with the Other segment – which includes its burgeoning at-home medical-supply operations – expected to produce 11% to 13% revenue growth and 15% to 18% profit growth in fiscal 2027.

The recent acquisition of AdaptHealth’s diabetes health business and Strive Medical for approximately $360 million is a prime example of this strategy. However, beneath the surface lies a more worrying trend: Cardinal’s reliance on a handful of large customers, with CVS Health accounting for 28% of its fiscal 2026 revenue. This customer concentration adds significant vulnerability to the company’s earnings, leaving it exposed to major contract losses or pricing concessions.

The real concern is not that Cardinal will fail to meet its growth targets – although this remains a possibility – but rather that its valuation has become detached from reality. With a forecasted adjusted EPS of $12.40 to $12.60 for fiscal 2027, the company’s stock price has already rerated close to its record high. If specialty growth slows or margins fall short, the shares could face a sharper valuation reset than they would have at their earlier multiple.

This trend reflects a broader issue in the healthcare sector: companies struggling to adapt to changing market conditions and regulatory pressures. Cardinal’s success in navigating this landscape is undeniable, but its vulnerability to external factors remains a significant concern.

As investors look ahead to fiscal 2027, one thing is clear: Cardinal Health’s growth momentum will be closely watched. While the company’s ability to execute on its strategy remains a key question mark, it also presents an opportunity for Cardinal to prove that its transformation has been more than just a rebranding exercise.

Cardinal’s story serves as a reminder of the delicate balance between growth and valuation in business. As investors, we would do well to remember that even the most impressive growth stories can be undone by external factors and internal vulnerabilities.